CD163 and neoplasm: CD163+ M2 macrophages, usually associated with immunosuppression, first increased post-capecitabine, further increased post-GCI and XRT, declined after the tumor vaccine immunotherapy, remained low through the suspected pseudo-progression on atezolizumab (+380d) and peaked again at relapse off-atezo.